Tag
Alzheimer’s
-
Q&A: What to know about new Alzheimer’s drug Leqembi
The FDA granted full clinical approval to Leqembi (lecanemab) on Thursday, July 6, making it only the second new drug…
-
Medicare announces coverage of costly Alzheimer’s medication. That could mean high premiums for beneficiaries
Medicare coverage of new Alzheimer’s treatments will raise premiums and increase out-of-pocket costs for beneficiaries, new analysis finds.
-
Global burden of Alzheimer’s projected to triple
Cases of Alzheimer’s disease are rising throughout the world and could triple by 2050, according to a recent analysis in The…
-
Disease-awareness campaigns merit extra scrutiny, experts say
This is part 2 of a package on sponsored disease awareness campaigns and other controversial drug marketing practices, focusing on…
-
Explaining Biogen’s controversial ‘MCI’ advertising to your audience
New marketing campaigns about forgetfulness and distraction could lead people to seek the costly Aduhelm drug for Alzheimer’s disease even…
-
Another Alzheimer’s treatment takes a different route than the rest
Editor’s Note: This is part 2 of a two-part package on the pipeline for Alzheimer’s disease drugs. Check out part…
-
Aside from Eli Lilly’s drug, what else is in the Alzheimer’s pipeline?
Eli Lilly recently announced that the FDA had granted a breakthrough therapy designation for donanemab, its investigational antibody therapy for…
-
New Alzheimer’s drug draws attention from federal, independent groups
Liz Seegert, AHCJ’s topic leader on aging, contributed to this article. Federal policy experts and the influential Institute for Clinical…
-
Alzheimer’s drug approved Monday by FDA raises questions for journalists
Part two of two parts; the first ran Thursday, June 10. There’s still a great deal we don’t yet understand…
-
FDA approves new Alzheimer’s drug, but controversy persists
Part one of two parts; the second runs tomorrow, Friday, June 11. You might think that the first new drug…